[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Michael J. Fox Foundation for Parkinson's Research\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":144},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,74,98,122],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100399177","ppmi-clinical---establishing-a-deeply-phenotyped-pd-cohort-100399177",false,"NCT04477785","PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort","The Parkinson's Progression Markers Initiative (PPMI) Clinical - Establishing a Deeply Phenotyped PD Cohort","PPMI","7.1 Healthy Controls (HC) Note: Active Healthy controls previously enrolled in PPMI do not require re-assessment of eligibility criteria listed below for enrollment in PPMI Clinical. Active participants do need to be able to provide informed consent for PPMI Clinical participation (includes use of a designated research proxy).\n\n7.1.1 Inclusion Criteria (HC)\n\n1. Male or female age 57 years or older at Screening visit.\n2. Individuals taking any of the following drugs: alpha methyldopa, methylphenidate, amphetamine derivatives or modafinil, must be willing and medically able to hold the medication for at least 5 half-lives before SPECT imaging.\n3. Confirmation that participant is eligible based on Screening SPECT imaging.\n4. Able to provide informed consent.\n5. Either is male, or is female and meets additional criteria below, as applicable:\n\n   * Female of childbearing potential who is not pregnant, lactating, or planning pregnancy during the study and has a negative pregnancy test on day of Screening SPECT imaging test prior to injection of DaTscanTM.\n\n7.1.2 Exclusion Criteria (HC)\n\n1. First degree relative with PD (i.e., biologic parent, sibling, child).\n2. Current or active clinically significant neurological disorder (in the opinion of the Investigator).\n3. Previously obtained MRI scan with evidence of clinically significant neurological disorder (in the opinion of the Investigator).\n4. Received any of the following drugs: dopamine receptor blockers (neuroleptics), metoclopramide and reserpine within 6 months of Screening visit.\n5. Current treatment with anticoagulants (e.g., coumadin, heparin, oral thrombin inhibitors) that might preclude safe completion of the lumbar puncture.\n6. Condition that precludes the safe performance of routine lumbar puncture, such as prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant coagulopathy or thrombocytopenia.\n7. Any other medical or psychiatric condition or lab abnormality, which in the opinion of the investigator might preclude participation.\n8. Any other reason that, in the opinion of the investigator, would render the participant unsuitable for study enrollment.\n\n7.2 Parkinson's Disease (PD) Note: Active PD participants previously enrolled in PPMI do not require re-assessment of eligibility criteria listed below for enrollment in PPMI Clinical. Active participants do need to be able to provide informed consent for PPMI Clinical participation (includes use of a designated research proxy).\n\n7.2.1 Inclusion Criteria (PD)\n\n1. Male or female age 30 years or older at Screening Visit.\n2. A diagnosis of Parkinson's disease for 2 years or less at Screening Visit.\n3. Not expected to require PD medication within at least 6 months from Baseline.\n4. Patients must have at least two of the following: resting tremor, bradykinesia, rigidity (must have either resting tremor or bradykinesia); OR either asymmetric resting tremor or asymmetric bradykinesia.\n5. Hoehn and Yahr stage I or II at Baseline.\n6. Individuals taking any of the following drugs: alpha methyldopa, methylphenidate, amphetamine derivatives or modafinil, must be willing and medically able to hold the medication for at least 5 half-lives before SPECT imaging.\n7. Confirmation that participant is eligible based on Screening SPECT imaging.\n8. Able to provide informed consent.\n9. Either is male, or is female and meets additional criteria below, as applicable:\n\n   * Female of childbearing potential who is not pregnant, lactating, or planning pregnancy during the study and has a negative pregnancy test on day of Screening SPECT imaging test prior to injection of DaTscanTM.\n\n7.2.2 Exclusion Criteria (PD)\n\n1. Currently taking levodopa, dopamine agonists, MAO-B inhibitors, amantadine or another PD medication, except for low-dose treatment of restless leg syndrome (with permission of medical monitor).\n2. Has taken levodopa, dopamine agonists, MAO-B inhibitors or amantadine within 60 days of Baseline visit.\n3. Has taken levodopa or dopamine agonists prior to Baseline visit for more than a total of 90 days.\n4. Atypical PD syndromes due to either drugs (e.g., metoclopramide, flunarizine, neuroleptics) or metabolic disorders (e.g., Wilson's disease), encephalitis, or degenerative diseases (e.g., progressive supranuclear palsy).\n5. A clinical diagnosis of dementia as determined by the investigator.\n6. Previously obtained MRI scan with evidence of clinically significant neurological disorder (in the opinion of the Investigator).\n7. Received any of the following drugs: dopamine receptor blockers (neuroleptics), metoclopramide and reserpine within 6 months of Screening visit.\n8. Current treatment with anticoagulants (e.g., coumadin, heparin, oral thrombin inhibitors) that might preclude safe completion of the lumbar puncture.\n9. Condition that precludes the safe performance of routine lumbar puncture, such as prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant coagulopathy or thrombocytopenia.\n10. Any other medical or psychiatric condition or lab abnormality, which in the opinion of the investigator might preclude participation.\n11. Any other reason that, in the opinion of the investigator, would render the participant unsuitable for study enrollment.\n\n7.3 Parkinson's Disease (PD) with LRRK2 or GBA variant Note: Active PD participants previously enrolled in PPMI do not require re-assessment of eligibility criteria listed below for enrollment in PPMI Clinical. Active participants do need to be able to provide informed consent for PPMI Clinical participation (includes use of a designated research proxy).\n\n7.3.1 Inclusion Criteria (PD ¬- LRRK2 or GBA)\n\n1. Male or female age 30 years or older at Screening Visit.\n2. A diagnosis of Parkinson's disease for 2 years or less at Screening Visit.\n3. Patients must have at least two of the following: resting tremor, bradykinesia, rigidity (must have either resting tremor or bradykinesia); OR either asymmetric resting tremor or asymmetric bradykinesia.\n4. Hoehn and Yahr stage I or II at Baseline.\n5. Confirmation of causative LRRK2 or GBA (willingness to undergo genetic testing as part of genetic screening and be informed of genetic testing results, or approved documentation of prior genetic testing results).\n6. Individuals taking any of the following drugs: alpha methyldopa, methylphenidate, amphetamine derivatives or modafinil, must be willing and medically able to hold the medication for at least 5 half-lives before SPECT imaging.\n7. Confirmation that participant is eligible based on Screening SPECT imaging.\n8. Able to provide informed consent.\n9. Either is male, or is female and meets additional criteria below, as applicable:\n\n   * Female of childbearing potential who is not pregnant, lactating, or planning pregnancy during the study and has a negative pregnancy test on day of Screening SPECT imaging test prior to injection of DaTscanTM.\n\n7.3.2 Exclusion Criteria (PD - LRRK2 or GBA)\n\n1. Received any of the following drugs: dopamine receptor blockers (neuroleptics), metoclopramide and reserpine within 6 months of Screening visit.\n2. Current treatment with anticoagulants (e.g., coumadin, heparin) that might preclude safe completion of the lumbar puncture.\n3. Condition that precludes the safe performance of routine lumbar puncture, such as prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant coagulopathy or thrombocytopenia.\n4. Any other medical or psychiatric condition or lab abnormality, which in the opinion of the investigator might preclude participation.\n5. Any other reason that, in the opinion of the investigator, would render the participant unsuitable for study enrollment.\n\n7.4 Parkinson's Disease (PD) with SNCA or rare genetic variant Note: Active PD participants previously enrolled in PPMI do not require re-assessment of eligibility criteria listed below for enrollment in PPMI clinical. Active participants do need to be able to provide informed consent for PPMI Clinical participation (includes use of a designated research proxy).\n\n7.4.1 Inclusion Criteria (PD - SNCA or rare genetic variant (such as Parkin or Pink1))\n\n1. Male or female age 30 years or older at Screening Visit.\n2. Parkinson's disease diagnosis at Screening Visit.\n3. Patients must have at least two of the following: resting tremor, bradykinesia, rigidity (must have either resting tremor or bradykinesia); OR either asymmetric resting tremor or asymmetric bradykinesia.\n4. Hoehn and Yahr stage I, II, or III at Baseline.\n5. Confirmation of causative SNCA or rare genetic variant (such as Parkin or Pink1) (willingness to undergo genetic testing as part of genetic screening and be informed of genetic testing results, or approved documentation of prior genetic testing results).\n6. Individuals taking any of the following drugs: alpha methyldopa, methylphenidate, amphetamine derivatives or modafinil, must be willing and medically able to hold the medication for at least 5 half-lives before SPECT imaging.\n7. Confirmation that participant is eligible based on Screening SPECT imaging.\n8. Able to provide informed consent.\n9. Either is male, or is female and meets additional criteria below, as applicable:\n\n   * Female of childbearing potential who is not pregnant, lactating, or planning pregnancy during the study and has a negative pregnancy test on day of Screening SPECT imaging test prior to injection of DaTscanTM.\n\n7.4.2 Exclusion Criteria (PD - SNCA or rare genetic variant (such as Parkin or Pink1))\n\n1. Received any of the following drugs: dopamine receptor blockers (neuroleptics), metoclopramide and reserpine within 6 months of Screening visit.\n2. Current treatment with anticoagulants (e.g., coumadin, heparin) that might preclude safe completion of the lumbar puncture.\n3. Condition that precludes the safe performance of routine lumbar puncture, such as prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant coagulopathy or thrombocytopenia.\n4. Any other medical or psychiatric condition or lab abnormality, which in the opinion of the investigator might preclude participation.\n5. Any other reason that, in the opinion of the investigator, would render the participant unsuitable for study enrollment.\n\n7.5 Prodromal Note: Active Prodromal participants previously enrolled in PPMI do not require re-assessment of eligibility criteria listed below for enrollment in PPMI Clinical. Active participants do need to be able to provide informed consent for PPMI Clinical participation (includes use of a designated research proxy).\n\nThe specific predictive eligibility criteria for participants recruited through PPMI Remote to advance to PPMI Clinical will be iteratively optimized based on data collected from these studies.\n\n7.5.1 Inclusion criteria (Prodromal)\n\nFor Screening:\n\n1. Confirmation that participant is eligible based on centrally determined predictive criteria including the University of Pennsylvania Smell Identification Test (UPSIT).\n\n   * For participants in PPMI Remote, referral to the clinical site confirms predictive eligibility.\n   * For participants identified by the clinical site, predictive criteria are based on generalized risk such as first degree biologic relative, known risk of PD including RBD, or known genetic variants associated with PD risk.\n\n   Additionally, confirmation of UPSIT eligibility during the Screening visit prior to SPECT Imaging.\n2. Male or female age 60 years or older (except age 30 years or older for SNCA, or rare genetic variants (such as Parkin or Pink1) participants).\n3. Individuals taking any of the following drugs: alpha methyldopa, methylphenidate, amphetamine derivatives or modafinil, must be willing and medically able to hold the medication for at least 5 half-lives before SPECT imaging.\n4. Able to provide informed consent.\n5. Either is male, or is female and meets additional criteria below, as applicable:\n\n   • Female of childbearing potential who is not pregnant, lactating, or planning pregnancy during the study and has a negative pregnancy test on day of Screening SPECT imaging test prior to injection of DaTscanTM.\n\n   For continuation to Baseline visit and ongoing follow-up:\n6. Confirmation that participant is eligible based on \\*Screening SPECT imaging.\n\n   * Screening SPECT Imaging eligibility:\n\nBased on the results of the SPECT imaging test, Prodromal participants eligible to continue their participation in PPMI Clinical will be asked to return for their PPMI Clinical baseline visit. Neither the participant nor the site investigator will be made aware of the participant's DAT status during the study.\n\n* It is anticipated that approximately 6,000 participants will complete a screening visit to undergo DAT imaging. Approximately 2,000 participants will be eligible to continue their participation in PPMI Clinical (those not eligible to proceed will remain in PPMI Remote, as applicable).\n* All participants with DAT deficit will be eligible to continue their participation in PPMI Clinical. It is estimated that about 75% of eligible participants will have a DAT deficit (defined by a hybrid of visual assessment and quantitative striatal specific binding analysis).\n* Some participants without DAT deficit will also be eligible to continue their participation in PPMI Clinical. These participants will be chosen based on DAT binding that is reduced from age expected but it not outside the normal range and\u002For from individuals with high-risk of PD including RBD, LRRK2, GBA, SNCA, or rare genetic variants (such as Parkin or Pink1) that do not demonstrate DAT deficit. It is estimated that about 25% of eligible participants will not have a DAT deficit.\n* It is anticipated that approximately 30% of the PPMI Clinical prodromal participants with DAT deficit will phenoconvert to motor parkinsonism during a 3 to 5-year follow-up.\n\n7.5.2 Exclusion Criteria (Prodromal)\n\n1. Clinical diagnosis of PD at screening, other parkinsonism, or dementia.\n2. Received any of the following drugs: dopamine receptor blockers (neuroleptics), metoclopramide and reserpine within 6 months of Baseline Visit.\n3. Current treatment with anticoagulants (e.g. coumadin, heparin) that might preclude safe completion of the lumbar puncture.\n4. Condition that precludes the safe performance of routine lumbar puncture, such as prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant coagulopathy or thrombocytopenia.\n5. Any other medical or psychiatric condition or lab abnormality, which in the opinion of the investigator might preclude participation.\n6. Currently taking levodopa, dopamine agonists, MAO-B inhibitors, amantadine or another PD medication, except for low-dose treatment of restless leg syndrome (with permission of medical monitor).\n7. Has taken levodopa, dopamine agonists, MAO-B inhibitors or amantadine within 60 days of Baseline visit. except for low-dose treatment of restless leg syndrome (with permission of medical monitor).\n8. Any other reason that, in the opinion of the investigator, would render the participant unsuitable for study enrollment.",true,"ALL","30 Years",{"count":21,"type":22},4500,"ESTIMATED","OBSERVATIONAL","The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls.\n\nThe overall goal of PPMI is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.",[26],"Parkinson Disease",[28,29,30,31,32,33,34,35],"Parkinson","Bio-markers","Neurodegenerative disorder","Imaging","Prodromal","Genetics","At Risk","Loss of Smell","RECRUITING","2026-06-10",{"date":39,"type":40},"2026-06-12","ACTUAL",{"date":42,"type":40},"2020-07-01",{"date":44,"type":22},"2033-12",{"name":46,"class":47},"Michael J. Fox Foundation for Parkinson's Research","OTHER",50,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":17,"sex":18,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100571386","black-and-african-americans-connections-to-parkinsons-disease-blaac-pd-100571386","NCT06719583","Black and African Americans Connections to Parkinson's Disease (BLAAC PD)","Black and African Americans Connections to Parkinson's Disease (BLAAC PD) A Project of the Global Parkinson's Genetics Program (GP2)","BLAAC PD","Inclusion Criteria for Control Participants:\n\n* Ability to provide informed consent\n* Age 50 years or older\n* Self-identify as Black or African American\n\nExclusion Criteria for Control Participants:\n\n* Diagnosis of Parkinson's Disease and\u002For neurological condition\n* Familial history of PD and\u002For neurodegenerative or psychiatric conditions\n* Unknown family history of PD and\u002For neurodegenerative or psychiatric conditions\n* Any conditions that, in the investigator's opinion, preclude the individual's ability to carry out study activities\n* If submitting a saliva sample, nothing by mouth (food, drink, gum, tobacco, or smoking) for 30 minutes prior to sample collection\n\nInclusion Criteria for Participants with a Diagnosis of PD:\n\n* Ability to provide informed consent\n* Age 18 years or older\n* Self-identify as Black or African American\n* Meet the Movement Disorder Society's clinical diagnostic criteria for Parkinson's disease\n\nExclusion Criteria for Participants with a Diagnosis of PD:\n\n\\- If submitting a saliva sample, nothing by mouth (food, drink, gum, tobacco, or smoking) for 30 minutes prior to sample collection","18 Years",{"count":59,"type":22},2000,"BLAAC PD is a research study to understand what Parkinson's disease looks like for Black and African American communities.\n\nBLAAC PD is happening at research centers around the United States. The study is part of the Global Parkinson's Genetics Program (GP2). GP2 is a research project working to transform understanding of the genetics of Parkinson's disease and make that knowledge globally relevant.",[26],[63,64],"genetics","underrepresented","2026-02-25",{"date":67,"type":40},"2026-02-27",{"date":69,"type":40},"2020-11-16",{"date":71,"type":22},"2027-12-31",{"name":46,"class":47},12,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":18,"minAge":57,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},"100613362","phase-2-early-longitudinal-imaging-in-the-parkinsons-progressive-marker-initiative-ppmi-using-18fav-133-ppmi-av-133-prodromal-imaging-100613362","NCT07265596","Early Longitudinal Imaging in the Parkinson's Progressive Marker Initiative (PPMI) Using (18F)AV-133 (PPMI AV-133 Prodromal Imaging)","Early Longitudinal Imaging in the Parkinson's Progression Markers Initiative Using [18F] AV-133 (PPMI AV-133 Prodromal Imaging)","Inclusion Criteria:\n\n1. A Prodromal PD participant, over the age of 18, confirmed as eligible to proceed to PPMI Clinical Baseline visit.\n2. Able to provide informed consent.\n3. Male or Female (females must meet additional criteria specified below as applicable)\n\n   * Females must be of non-childbearing potential or using a highly effective method of birth control 14 days prior to until at least 24 hours after injection of 18F-AV-133\n\n     * Non-childbearing potential is defined as a female that must be either postmenopausal (no menses for at least 12 months prior to PET scan) or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy).\n     * Highly effective method of birth control is defined as practicing at least one of the following: A birth control method that results in a less than 1% per year failure rate when used consistently and correctly, such as oral contraceptives for at least 3 months prior to injection, an intrauterine device (IUD) for at least 2 months prior to injection, or barrier methods, e.g., diaphragm or combination condom and spermicide. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) is not acceptable.\n   * Females of childbearing potential must not be pregnant, breastfeeding or lactating.\n\n     * Includes a negative urine pregnancy test prior to injection of 18F-AV-133 on day of PET scan.\n\nExclusion Criteria:\n\n1. Received any of the following medications that might interfere with 18F- AV-133 PET imaging: tetrabenazine (TBZ) or methylphenidate, reserpine, or amphetamine derivative, within 1 month prior to the Baseline 18F-AV-133 injection.\n2. Any other medical or psychiatric condition or lab abnormality, which in the opinion of the investigator might preclude participation.",{"count":82,"type":22},100,"INTERVENTIONAL",[85],"PHASE2","The study is a longitudinal, multi-center study to assess progression of \\[18F\\] AV-133 imaging in Prodromal PD participants. Participants will be followed for up to 24 months. Approximately 100 Prodromal participants will be recruited from up to 10 sites. Participants will be comprehensively assessed at baseline and follow up. Participants will undergo imaging assessments with \\[18F\\] AV-133 and clinical (motor, neuropsychiatric, cognitive and imaging and biomarker) assessments (conducted under the PPMI Clinical protocol).",[88],"Prodromal Parkinsons Disease","2025-11-24",{"date":91,"type":40},"2025-12-05",{"date":93,"type":40},"2023-10-30",{"date":95,"type":22},"2027-12",{"name":46,"class":47},8,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":17,"sex":18,"minAge":105,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":83,"phases":109,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":121},"100594483","phase-2-evaluation-of-tau-pathology-in-sporadic-and-lrrk2-parkinsons-disease-100594483","NCT07020026","Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease","Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease Using [18F]PI-2620: A High-resolution PET Imaging Study Using NeuroEXPLORER (NX PI-2160 in PD)","Inclusion Criteria:\n\nGeneral inclusion criteria include the following:\n\n1. Ability to comply with the study procedures and attend follow-up visits.\n2. Written informed consent from the participant or legal guardian.\n3. Male or Female between 45 years and 85 years of age (Females must meet additional criteria specified below, as applicable) a. Females must be of non-childbearing potential or using a highly effective method of birth control 14 days prior to until at least 24 hours after injection of \\[18F\\]PI-2620 or DaTscan.\n\ni. Non-childbearing potential is defined as a female that must be either postmenopausal (no menses for at least 12 months prior to PET scan) or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy).\n\nii. Highly effective method of birth control is defined as practicing at least one of the following: A birth control method that results in a less than 1% per year failure rate when used consistently and correctly, such as oral contraceptives for at least 3 months prior to injection, an intrauterine device (IUD) for at least 2 months prior to injection, or barrier methods, e.g., diaphragm or combination condom and spermicide. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) is not acceptable.\n\nb. Females of childbearing potential must not be pregnant, breastfeeding or lactating, or planning pregnancy during the duration of the study.\n\nc. Non PPMI participant females of childbearing potential must have a negative serum pregnancy test at Screening and all females of childbearing potential must have negative urine pregnancy test prior to \\[18F\\]PI-2620 injection on day of Baseline PET scan.\n\nd. Non PPMI participant females of childbearing potential must have a negative urine pregnancy test prior to Screening Visit DaTscan injection.\n\nHealthy Controls:\n\na) Enrolled in the PPMI study as a healthy subject.\n\nDisease specific inclusion criteria:\n\na) Parkinson's disease\n\na. Enrolled in the PPMI study as a sporadic PD or LRRK2 PD participant. b. Known CSF alpha synuclein seeding amplification assay status. c. Known Plasma phosphorylated Tau217 status. b) Progressive Supranuclear Palsy (PSP):\n\n1. Diagnosis of progressive supranuclear palsy (PSP) based on the Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria (Höglinger et al., 2017).\n2. Symptom onset within 2-5 years prior to screening.\n3. Progressive motor symptoms including vertical supranuclear gaze palsy, postural instability, and other signs of parkinsonism.\n4. Evidence of striatal degeneration in form of abnormal DaTscan (previously obtained DaTscan since onset of motor symptoms may be used).\n\nc) Corticobasal Syndrome (CBS):\n\n1. Diagnosis of corticobasal syndrome (CBS) based on clinical criteria, with asymmetric motor and cognitive dysfunction (Armstrong et al., 2013).\n2. Presence of limb apraxia, dystonia, alien limb phenomenon, and\u002For parkinsonism (e.g., rigidity, bradykinesia).\n3. Cognitive decline as indicated by impairment in attention, executive function, or memory.\n4. Evidence of striatal degeneration in form of abnormal DaTscan (previously obtained DaTscan since onset of motor symptoms may be used).\n\nExclusion Criteria:\n\n1. Any other medical or psychiatric condition or lab abnormality, which in the opinion of the investigator might preclude participation.\n2. For those receiving Screening DaTscan:\n\n   • Received any of the following medications that could interfere with the imaging and unwilling or medically unable to hold them for five half-lives before SPECT imaging: alpha methyldopa, methylphenidate, amphetamine derivatives or modafinil, bupropion, phentermine, phencyclidine, fentanyl, or medication commonly considered to interfere with Ioflupane binding per standard clinical practice.\n3. Received any of the following drugs: dopamine receptor blockers (neuroleptics), metoclopramide and reserpine, within 6 months of Screening Visit for non-PPMI participants or within 6 months of Baseline Visit for PPMI participants.\n4. Any structural abnormality or finding on previously obtained or screening brain MRI suggestive of clinically significant neurological disorders other than the diseases of interest (in the opinion of the investigator).\n5. Any other reason that in the opinion of the investigator, including abnormal labs, that could interfere with the safety with radiotracer injection, would render the participant unsuitable for the study enrollment.","45 Years","85 Years",{"count":108,"type":22},60,[85],"The study aims to evaluate the burden of tau pathology in people with Sporadic and LRRK2 PD via in vivo imaging using the tau tracer, \\[18F\\]PI-2620, and a high resolution PET camera, NeuroEXPLORER.",[112],"Parkinson's Disease","2025-06-05",{"date":115,"type":40},"2025-06-13",{"date":117,"type":40},"2025-05-12",{"date":119,"type":22},"2027-06",{"name":46,"class":47},1,{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":17,"sex":18,"minAge":57,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":131,"conditions":132,"keywords":133,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":121},"100444256","parkinson-progression-marker-initiative-online-ppmi-online-100444256","NCT05065060","Parkinson Progression Marker Initiative Online (PPMI Online)","Parkinson's Progression Markers Initiative Online Study (PPMI Online)","Inclusion Criteria:\n\n* Parkinson Disease (PD) Participants:\n\n  * Male or female age 18 years or older.\n  * Has received a diagnosis of Parkinson's disease\n\nParticipants without PD:\n\n* Male or female age 18 years or older.\n* Has not received a diagnosis of Parkinson's disease",{"count":130,"type":22},500000,"Parkinson Progression Marker Initiative Online (PPMI Online) is an observational study collecting participant reported information from people with and without Parkinson's disease (PD), for the goal of better understanding risk and predictive factors for PD.\n\nPPMI Online is part of the broader Parkinson Progression Marker Initiative aimed at identifying markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.",[26],[28,134,32,34,135],"Neurodegenerative Disorder","Participant Reported Outcomes","2024-11-21",{"date":138,"type":40},"2024-11-25",{"date":140,"type":40},"2021-07-28",{"date":142,"type":22},"2041-12",{"name":46,"class":47},""]